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DRSP’s reliability and responsiveness was also assessed. RESULTS: Studies showed 
women with PMDD experience severe physical and emotional symptoms at the luteal 
stage of the menstrual cycle (ﬁve days before menses), primarily as a result of hormonal 
ﬂuctuations associated with ovulation. Physical symptoms include: aches/pains; breast 
tenderness/swelling; bloating; weight gain; increased appetite/cravings; sleep problems; 
fatigue and difﬁculties concentrating. Emotional symptoms include: mood swings; 
depressed mood; anxiety/tension; anger; irritability; decreased interest; and feelings of 
being overwhelmed. The experience of these symptoms contributes to functional 
impairment in women with PMDD, particularly in terms of: social functioning; work/
school functioning; productivity; role functioning; relationships; and activities of daily 
living. A review of DRSP item content revealed all symptoms and impacts of PMDD 
are captured by the DRSP, supporting the face and content validity of the instrument. 
Studies also showed the DRSP to have acceptable internal consistency (Chronbach’s 
alpha q0.7), test-retest reliability (ICC correlations 0.67–0.99) and responsiveness to 
improvements following treatment (effect sizes 0.64 1.71). CONCLUSIONS: PMDD 
is associated with physical and emotional symptoms which can have a signiﬁcant 
impact on patients’ lives. The DRSP is a valid, reliable and responsive patient-reported 
tool for assessing PMDD-related symptoms and their impact. The DRSP could be 
useful for clinicians during general practice, or for clinical trials in identifying PMDD 
populations or the impact during treatment.
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OBJECTIVES: Little is known about preferences for technological developments of 
women undergoing fertility treatments. This study aims to investigate the preferences 
for ovarian stimulating hormone (OSH) therapies of infertile women undergoing 
assisted reproduction, to determine the utility values ascribed to different attributes 
of OSH treatments, and to estimate women’s willingness to pay (WTP) for OSH. 
METHODS: A representative sample of ambulatory patients ready to receive, or 
receiving, OSH therapies for infertility were recruited from seven specialized private 
centers in six Autonomous Communities in Spain. Both WTP and conjoint analysis 
(CA) were used to elicit preferences. Attributes and levels of OSH treatments were 
identiﬁed by literature review and two focus groups with experts and patients. WTP 
valuations were derived by double-bounded (closed-ended) and contingent ranking 
methods. RESULTS: 167 patients [mean age: 36 years (SD 4.2)] were interviewed. 
Most participants (53.9%) had a high education level (university degree), were 
married (77.2%), referred an estimated net income beyond a1500 per month (50.9%) 
and had paid between a501 and a1500 for their most recent hormonal treatment 
(57.6%). In 52% of cases, there was more than one cause of infertility (sperm related 
factors, 31%). Maximum WTP for an OSH treatment was a800 (median) per cycle, 
which exceeds previously reported cost per OSH cycle with combo therapies (a691.65), 
while 75% would pay a1500 or less. 56.8% were willing to pay additional a51–300 
for a 1–2% effectiveness gain. Utility values (CA) showed that effectiveness (37.0) was 
the most valued attribute (costs 24.9; safety 16.5; information sharing with physicians 
13.5). Cost of last OSH cycle and WTP shown positive correlation (r  0.203, p  
0.05). CONCLUSIONS: WTP for OSH therapies exceeds current cost. Additional 
WTP exists for 1–2% effectiveness improvement. Effectiveness and costs were the most 
important determinants of preferences, followed by safety and information sharing 
with physicians.
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OBJECTIVES: To investigate drug use six months before (SMBP) and during preg-
nancy (DP) among Serbian pregnant women (SPW). METHODS: Pharmacy based 
cross-sectional survey was conducted among SPW between March through April 
2009. Specially designed questionnaire was used for collecting data on socio-demo-
graphics, health status, and drug (Rx and over the counter) use. Vitamin and iron 
supplements were not included in the analysis. RESULTS: 260 SPW completed the 
questionnaire. 69.6% of SPW were 25–34 years old, 75.8% lived in the city area, the 
majority were high school or college graduates, and 55.4% were pregnant with their 
ﬁrst child. 9.4% of SPW had a chronic disease. There was not a statistically signiﬁcant 
decrease in the percentage of SPW taking drugs DP compared to SMBP (53.9% and 
53.0%, respectively), as well as in an average number of drugs taken (1.54 o 0.73 and 
1.45 o 0.66 drugs/women, respectively (range 1 to 4 before and during pregnancy)). 
The most frequently used drug classes by SPW were: analgetics/antipyretics, hormones, 
antiinfectives, tocolitics and anti-hypertensives (25.5%, 25.5%, 19.7%, 13.7%, and 
7.3%, respectively). The most frequently used analgetic/antipyretic was paracetamol 
(62.83%), while the most frequently used anti-infectives were penicillins and cepha-
losporins (77.0%). The only used tocolitics were fenoterol and hexoprenaline and the 
only used hormones were dydrogesterone and progesterone. Drugs that were used 
belonged to these FDA fetal risk categories B, C, and D (diazepam, alprazolam and 
diclofenac in the 3rd trimester) (52.6%, 26.3%, and 15.8% respectively). SPW did not 
use drugs in the FDA category X. Before pregnancy folic acid usage was low (5.5% 
PW) while during the 1st, 2nd and 3rd trimester of pregnancy usage was 69.96%, 
15.05%, 5.93%, respectively. CONCLUSIONS: Differences in drug use DP and 
SMBP among SPW was negligible. The most frequently used drug classes during 
pregnancy were: analgetics/antipyretics, hormones, antiinfectives, tocolitics and 
antihypertensives.
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OBJECTIVES: The comparison among diverse regions and populations is one of the 
important issues on the study of quality of life (QoL). This study demonstrated that 
how Geographic Information System (GIS) can help us on the study of QoL. By 
mapping the QoL scores and objective QoL-related data on regional maps, GIS help 
us to interpret the QoL data more intensively. METHODS: The QoL data was col-
lected from the 2001 National Health Interview Survey (NHIS) in Taiwan. 13,010 
participants were randomly selected to complete the WHOQOL-BREF (Taiwan 
version). Mean scores of the four QoL domains were used for each of the 25 admin-
istrative divisions. This study also collected 41 objective QoL-related variables for 
each of the divisions from the 2001 National Statistics. The variables include the facets 
of demography, public security, medical resource, welfare, level of education, occupa-
tion structure, ﬁnancial state, and environment. All variables were illustrated on the 
map of Taiwan by GIS with gradient colors. The correlation coefﬁcients between QoL 
domain scores and these objective variables were also calculated. RESULTS: Based 
on the correlation coefﬁcients, no signiﬁcant correlation was found between psycho-
logical domain score and the objective variables. Four, three, and eleven variables were 
statistically correlated with physical, social, and environmental domain scores respec-
tively. In comparisons of the GIS maps between QoL and the objective variables, 
interpretation on the QoL distribution became easier. In general, QoL decreased from 
northwest to southeast. The signiﬁcant correlation coefﬁcients indicated that ﬁnancial 
state, occupation structure and level of education were comparatively related to QoL 
which were conﬁrmed by the GIS maps. CONCLUSIONS: In this study, we demon-
strate the GIS technology can be an assistant to study the regional distribution of QoL. 
Moreover, objective QoL-related variables can be combined to interpret the QoL dis-
tribution intensively. This approach may be beneﬁcial for policy making.
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OBJECTIVES: POSSIBLE EU® is an ongoing, prospective observational study explor-
ing the experience of postmenopausal women receiving bone loss medications in 
Europe. We previously reported that these women had substantially impaired HRQoL. 
This baseline analysis identiﬁes potential important predictors of HRQoL in these 
women. METHODS: A total of 3402 women were enrolled in 3 treatment cohorts: 
established (treated q1 year), inception (initiating) or switching treatment. Clinical 
data and HRQoL (including EQ-5D) were collected at baseline (N  3011). A multi-
variable analysis model was ﬁtted to identify determinants of EQ-5D score. The linear 
relationship of each variable was assessed using a forward selection process (entry 
level 0.05). The non-linear relationship of the selected variables with the outcome, 
were assessed using natural logarithmic and cubic spline transformations Analyses 
were performed using SAS software, version 9.1 and GNU R. RESULTS: For the full 
analysis set, median age (Q1, Q3) was 69 (61, 76) years; women had a median of 3 
ongoing comorbid conditions at baseline. A high proportion of patients had hyperten-
sion (44%), ongoing back pain (41%), osteoarthritis (34%) hyperlipidaemia (32%), 
ongoing upper GI issues (18%), prior vertebral fractures (13%), and depression 
(13%). For the 3011 patients, 12 variables were signiﬁcantly associated with EQ-5D 
score, explaining 39.4% of the residual variance (Table). CONCLUSIONS: In Euro-
pean women who are receiving/initiating bone loss medication, any prior vertebral 
fracture, ongoing depression, fear of falling, number of ongoing comorbid conditions, 
upper GI issues and back pain are prevalent, and strongly predictive, of lower HRQoL. 
Table: Determinants of EQ-5D utility [0 to 1 continuous score]: The effects are 
 Intercept: 0.1801, 0.1083, 0.486, 0.2195; Inception vs. Established*: 0.04862, 
0.06822, 0.02903, .0001; Switch vs. Established*: 0.01271, 0.03901, 0.01360, 
0.3435; Lack of fear of falling: 0.00545, 0.005092, 0.005808, .0001; Ongoing 
depression: 0.1076, 0.1345, 0.08076, .0001; Any prior vertebral fractures: 
0.09239, 0.1225, 0.06223, .0001; Number of ongoing comorbid conditions: 
0.01122, 0.01773, 0.00471, 0.0007; Ongoing upper GI (GERD, reﬂux, dyspep-
sia): 0.04067, 0.06549, 0.01586, 0.013; Ongoing back pain: 0.03455, 0.05594, 
0.01316, 0.0016; BMI: 0.00298, 0.0049, 0.00105, 0.0024; Ongoing seizure 
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disorders: 0.1263, 0.2265, 0.02604, 0.0136; (Log) Number of previous fractures: 
0.02572, 0.004297, 0.04713, 0.0186; (Log) Age: 0.07413, 0.008808, 0.1394, 0.0261; 
Ongoing congestive: 0.06264, 0.006147, 0.1191, 0.0298 for Parameter Estimate, 
Lower 95% CI, Upper 95% CI, P value, respectively. *Cohort p  0.0001 Deﬁned by 
OPAG. Investigator site included as a random effect.
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Venous disease (VD) is characterized by an impairment of the ﬂaps or small valves, 
Currently, VD constitutes a real medical problem as well as a real socio-professional 
disability because of its physical symptoms. The quality of life (qol) of the patients is 
affected by this problem. OBJECTIVES: Assess, in real-life conditions, the impact of 
a Vitamin C, Ruscus and hesperidin methyl-chalcone based treatment, on the quality 
of life of patients with venous disease. METHODS: Pragmatic assessment in real-life 
conditions over a 7-day period with the pharmacist handing out the questionnaire 
when the treatment is delivered. The SQOR-V, a validated questionnaire available in 
several languages, was used. RESULTS: A total of 76 women were included, average 
age 48.95, average weight 63.5 kg with an average BMI of 23.8, 29% with a BMI 
higher than 25 and 79% are non smoking and 38% exercise regularly. 49% have a 
professional activity, of which 51% are required to stand for more than 6 hrs, and 
20% say they must stand without any rest. One patient in 3 believes that her discom-
fort (36%), complaints (36%) and pain (34%) had improved as soon as the 3rd day. 
On the 7th day, 2 in 3 patients believed that their discomfort (59%), complaints (58%) 
and their pain (61%) had improved. Seventy-nine percent of the patients declared 
being satisﬁed and 74% would recommend this treatment. This data is conﬁrmed 
through the qol life assessment. In fact, the qol assessment questionnaire SQOR-V 
shows a score of 45.24 at the time of inclusion, which became 39.66 at the end of 
the 7-day treatment period. The qol improvement is statistically signiﬁcant (p  0.03) 
CONCLUSIONS: The treatment shows its effectiveness in 7 days through a statisti-
cally signiﬁcant improvement of qol. This subjective data is conﬁrmed by the patients’ 
satisfaction expressed through the renewal of the treatment and recommending it to 
people they know.
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OBJECTIVES: Changed morbidity patterns in many industrialised countries lead to 
new requirements concerning the health care process. In contrast to a complete cure 
and due to increasing multiple chronic conditions with longevity, the alleviation of 
complaints and thereby securing the health-related quality of life (HRQoL) is more 
and more in the focus of efforts. Aim of this study is to analyse the effects of multiple 
chronic conditions on HRQoL in elderly people (q70 years). METHODS: Based on 
data from the getABI cohort (PRISCUS), empirical analyses were conducted. To evalu-
ate HRQoL a representative sample of 2,120 older participants (76.29 o 4.48 years, 
46.3% male) from Germany provided information on their current health status and 
completed the EQ-5D and the SF-8-questionnaires. RESULTS: Findings show clearly, 
that the existence of multiple chronic conditions (and not the ageing alone) has nega-
tive effects on HRQoL (p  0.000). There is an inverse relationship between HRQoL 
and multimorbidity in the elderly. In comparison to mental dimensions (p  0.234), 
physical domains are affected signiﬁcantly stronger by an increasing number of dis-
eases (p  0.000). Particularly new cardiovascular and cerebrovascular diseases in the 
last two years, the long-term existence of peripheral arterial disease and dysfunctions 
of the musculoskeletal system result in severe losses of HRQoL. On the contrary, other 
chronic conditions (hypertension, diabetes, lipometabolic disorder) or events more 
than two years ago do not have signiﬁcant inﬂuence on HRQoL. CONCLUSIONS: 
A clear understanding of the impacts of speciﬁc morbidity patterns on HRQoL in 
elderly persons can help to ensure an extensive and comprehensive health care process 
and to optimise it in the patients´ sense. This optimised process should not separate 
between single diagnoses, but focus on the concurrence of multiple conditions.
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OBJECTIVES: The aim of this study was to determine the reliability and validity of 
the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ) for Turkish 
women. METHODS: The data were collected through sociodemograﬁc questionnaire, 
QLESQ and EuroQol. The scale, which was translated into English from Turkish, 
again translated back into English by two independent translators, was applied to 168 
female subjects. The females above 25 consisted of 85 housewives and 83 working 
women. The scale was applied to 74 females in the pretest phase. The EuroQol-5D 
was used for concurrent validity. The EuroQol-5D was used for concurrent validity. 
Cronbach’s Alfa was used to assess reliability, and factor analysis to assess dimen-
sionality. RESULTS: The internal consistency coefﬁcient (Cronbach’s alpha) of 
QLESQ was 0.93. Factor analysis of the scale revealed that it was composed of three 
factors with Eigenvalues 2, accounting for 62.0% of the total variance. All items of 
the Turkish QLESQ had a factor load ranging from 0.22 to 0.76 There was a strong 
relationship between QLESQ, and EuroQoL 5D. CONCLUSIONS: The QLESQ has 
good validity and reliability for Turkish women.
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OBJECTIVES: Willingness to pay (WTP) per quality-adjusted life year (QALY) has 
been suggested as the threshold of cost-effectiveness analysis (CEA) in evaluating 
health technology. This study is to estimate the WTP/QALY in Chinese patients with 
chronic prostatitis (CP). METHODS: A consecutive sample of CP outpatients who 
visited 306 Hospital of PLA in Beijing, China at the beginning of 2009 was recruited. 
Their health related utility was assessed through EQ-5D and SF-6D; and their health 
status with EQ-VAS and National Institutes of Health-Chronic Prostatitis Symptom 
Index. A closed-ended iterative bidding contingent valuation method was used to elicit 
WTP for a hypothetical perfect health. WTP/QALY was calculated with the utility 
and WTP value elicited in this study. Multiple linear regression model was run to 
identify the effect of factors on the magnitude of WTP/QALY. RESULTS: After 
informed consent, 178 CP patients participated in the study. Mean (SD) EQ-5D and 
SF-6D utility weights were comparable at 0.74 (0.13) and 0.75 (0.09) respectively. 
WTP/QALY were estimated at US$8197 with EQ-5D and US$7684 with SF-6D, 
which were much lower than the often-cited threshold of cost-effectiveness analysis. 
Compared with the threshold recommended by World Health Organization, which is 
1–3 times of gross domestic product per capita, WTP/QALY from this study were also 
at the lower bound. Working and unmarried Patients with higher household income 
were willing to pay more for a QALY. CONCLUSIONS: As the ﬁrst study to estimate 
the WTP/QALY in China, this study demonstrated that question for WTP in this study 
is acceptable and feasible in Chinese CP patients, and the method to calculate WTP/
QALY produced meaningful answers. The lower WTP/QALY compared with the 
often-cited threshold of CEA suggests that WTP/QALY elicited from patients may not 
provide insight into societal valuations of medical expenditures.
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OBJECTIVES: Benzodiazepine (BZD) treatment of prolonged periods and higher 
dosage is not recommended for the elderly. Because of free choice of physicians and 
the absence of gatekeepers in Taiwan, this study aimed to identify prescription patterns 
and expenditure for long-term BZD treatment in elderly outpatients, and examine 
factors associated with the prescription overlap. METHODS: This study used a sam-
pling database from the Bureau of National Health Insurance. Subjects were included 
if they were aged 65 or over and had received any BZD prescription in 2002. Received 
BZDs were divided into prescribed and overlapped quantities in terms of deﬁned daily 
doses (DDDs) and expenditure. Single long-term prescriber was deﬁned as receiving 
more than 180 supply days from one department. The logistic model and multivariate 
regression models were used to evaluate associations of factors with the prescription 
overlap and quantities of overlap, respectively. RESULTS: In 2002, 1705 out of 7561 
elderly individuals had received BZDs with more than 180 prescription-covered days. 
Prescription overlap represented 10% of both their DDDs and expenditure. There 
were 107 subjects who had no single long-term prescriber and 362 subjects with more 
than 30 prescription-overlap days. Men, mental illness(es), comorbidities, multiple 
prescribers with or without a single long-term prescriber, and higher prescribed dose 
were associated with an increased likelihood of prescription overlap. Increased age, 
depression, a single long-term prescriber with or without multiple prescribers, and 
increased prescribed dose were correlated with increased overlapped DDD and expen-
diture. CONCLUSIONS: Eighteen percent of the elderly with long-term BZD treat-
ment were not under the authority of a single prescriber, and the prescription overlap 
was highly concentrated in 21% of them. Multiple prescribers increased the probabil-
ity of prescription overlap. Individuals with a single long-term prescriber and multiple 
prescribers had a higher risk of prescription overlap, and higher overlapped BZD 
DDDs and expenditure.
